Registry for Germ Cell and Testicular Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a registry to enhance understanding of germ cell tumors and testicular tumors. It will include individuals diagnosed with these tumors, their relatives, and unrelated individuals without these tumors. By collecting data through questionnaires and biological samples, the study seeks to investigate the prevention, diagnosis, treatment, and outcomes associated with these tumors. The involvement of relatives and controls will help identify genetic and environmental factors influencing tumor development.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Case Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must have a diagnosis or suspicion of germ cell tumor and/or a testicular mass

Family Member Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must be a blood relative of the proband. Family members of probands are eligible. These individuals need not have a diagnosis of GCT-TT, as they will be used for segregation analysis of suspected variants found in the proband.

Control Cohort

* Must be ≥ 18 years of age AND
* Must be an English-speaker AND
* Must not have a personal history of cancer, with the exception of non-melanoma skin cancer, AND
* Must not have a family history of germ cell tumor or testicular tumor AND
* Must not be a blood relative of controls enrolled in this study

Exclusion Criteria:

Where it's running

• Memorial Sloan Kettering Basking Ridge
  Basking Ridge, New Jersey, United States Recruiting
• Memorial Sloan Kettering Monmouth
  Middletown, New Jersey, United States Recruiting
• Memorial Sloan Kettering Bergen
  Montvale, New Jersey, United States Recruiting
• Memorial Sloan Kettering Commack
  Commack, New York, United States Recruiting
• Memorial Sloan Kettering Westchester
  Harrison, New York, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Darren Feldman, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Darren Feldman, MD
• Phone: 646-422-4491

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Teniposide plus cisplatin for newly diagnosed central malignant germ cell tumors

  This trial tests whether giving teniposide together with cisplatin helps people newly diagnosed with central malignant germ cell tumors.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07188441

• ZW251 for advanced liver, lung, and germ cell cancers

  This will test whether ZW251, an antibody-drug conjugate that targets GPC3, is safe and can shrink tumors in adults with advanced hepatocellular carcinoma, squamous cell non-small cell lung cancer, or germ cell tumors.

  Recruiting at 25 sites Phase 1 Zymeworks BC Inc. · San Francisco, California and 24 other locations · NCT07164313

• Maintenance zanzalintinib with oral etoposide after high-dose chemotherapy for germ cell tumor

  This treatment tests whether daily zanzalintinib together with cycles of oral etoposide can help people with relapsed or refractory germ cell tumors after high-dose chemotherapy and stem-cell transplant.

  Recruiting Phase 1/2 Indiana University · Indianapolis, Indiana · NCT06937866

• Low-dose aspirin to prevent venous blood clots during chemotherapy for advanced germ cell (testicular) cancer

  This trial will see if taking one daily low-dose aspirin (81 mg) during cisplatin chemotherapy prevents venous blood clots over six months in adults up to age 70 with high-risk advanced germ cell or testicular cancer.

  Recruiting at 3 sites Phase 2 Wake Forest University Health Sciences · Charlotte, North Carolina and 2 other locations · NCT06866964

• Creating a database for mediastinal tumors at Peking Union Medical College Hospital

  This study is creating a database to help doctors better understand and treat different types of mediastinal tumors by collecting information on their characteristics and imaging results.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06421805

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.